Tuğba YÖRÜK HAZAR, Bijen NAZLIEL, Ceyla İRKEÇ, Aslı AKYOL GÜRSES, Hale BATUR ÇAĞLAYAN

High serum S-100B protein levels within the first 36 hours of acute ischemic stroke predicts high NIHSS scores

Aim: The aim of the present study was to evaluate serum levels of S-100B which is an acidic calcium-binding protein within thefirst 36 hours following an acute ischemic stroke and to determine the correlation between S-100B levels and National Institutes ofHealth Stroke Scale (NIHSS) scores.Material and Methods: Fifty patients with ischemic stroke (25 male, 25 female; mean age=64) and 30 healthy volunteers (14 male,16 female; mean age=61) serving as age and sex matched controls were included in this study. Venous blood samples were takenwithin the first 36 hours following the acute stroke. The quantitative determination of S-100B in serum was carried out using anenzyme linked immunosorbent assay.Results: Patients with acute ischemic stroke had significantly higher serum S-100B protein concentrations (42 pg/ml) than thoseof normal controls (31.5 pg/ml) (p

PDF

___

1. Bonaventura A, Liberale L, Vecchie A, et al. Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. Int J Mol Sci 2016;17.
2. Rezaei O, Pakdaman H, Gharehgozli K, et al. S100 B: A new concept in neurocritical care. Iran J Neurol 2017;16:83-9.
3. Buttner T, Weyers S, Postert T, et al. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke; J Cerebral Circulation 1997;28:1961-5.
4. Wang S, Wang L, Zhang X, et al. Effects of subcutaneous low molecular weight heparin and intravenous unfractionated heparin on serum S100 concentrations in patients with cerebrovascular diseases. Clinical chemistry and laboratory medicine : CCLM / FESCC 2012;50:525-8.
5. Rothermundt M, Peters M, Prehn JH, et al. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003;60:614-32.
6. Foerch C, Otto B, Singer OC, et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke; J Cerebral Circulation 2004;35:2160-4.
7. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke; J Cerebral Circulation 1989;20:864-70.
8. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-6.
9. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke; J Cerebral Circulation 1993;24:35-41.
10. Brea D, Sobrino T, Blanco M, et al. Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2009;47:1513-8.
11. Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke; J Cerebral Circulation 2007;38:2491-5.
12. Steiner J, Bernstein HG, Bielau H, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neuroscience 2007;8:2.
13. Dassan P, Keir G, Brown MM. Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B. Cerebrovascular Diseases 2009;27:295-302.
14. Stroick M, Fatar M, Ragoschke-Schumm A, et al. Protein S-100B - A prognostic marker for cerebral damage. Curr Med Chem 2006;13:3053-60.
15. Fujiya A, Nagasaki H, Seino Y, et al. The role of S100B in the interaction between adipocytes and macrophages. Obesity (Silver Spring) 2014;22:371-9.
16. Hardemark HG, Ericsson N, Kotwica Z, et al. S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. J Neurosurg Pediatr 1989;71:727-31.
17. Persson L, Hardemark HG, Gustafsson J, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke; Journal of Cerebral Circulation 1987;18:911-8.
18. Abraha HD, Butterworth RJ, Bath PM, et al.Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann Clin Biochem 1997;34:546-50.
19. Fassbender K, Schmidt R, Schreiner A, et al. Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 1997;148:101-5.
20. Missler U, Wiesmann M, Friedrich C, et al. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke; Journal of Cerebral Circulation 1997;28:1956-60.
21. Elting JW, de Jager AE, Teelken AW, et al. Comparison of serum S-100 protein levels following stroke and traumatic brain injury. J Neurol Sci 2000;181:104-10.
22. Herrmann M, Vos P, Wunderlich MT, et al. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke; J Cerebral Circulation 2000;31:2670-7.
23. Wunderlich MT, Wallesch CW, Goertler M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci 2004;227:49-53.
24. Foerch C, Singer OC, Neumann-Haefelin T, et al. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005;62:1130- 4.
25. Jauch EC, Lindsell C, Broderick J, et al. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke; J Cerebral Circulation 2006;37:2508-13.
26. Abdel-Ghaffar WE, Ahmed S, Elfatatry A, et al. The role of s100b as a predictor of the functional outcome in geriatric patients with acute cerebrovascular stroke. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 2019;55:75.
27. Cunningham RT, Young IS, Winder J, et al. Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction. Eur J Clin Invest1991;21:497-500.
28. Wunderlich MT, Ebert AD, Kratz T, et al. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke; J Cerebral Circulation 1999;30:1190-5.
29. Gonzalez-Garcia S, Gonzalez-Quevedo A, FernandezConcepcion O, et al. Short-term prognostic value of serum neuron specific enolase and S100B in acute stroke patients. Clinical Biochemistry 2012;45:1302- 7.
30. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-4.
31. Lin CH, Tsai YH, Lee JD, et al. Magnetic Resonance Perfusion Imaging Provides a Significant Tool for the Identification of Cardioembolic Stroke. Curr Neurovasc Res 2016;13:271-6.